The sexiness in the stock existed before the failed trials. Andrew McLean has now 'cleared the decks' with the one off write off of the clinical and R&D impairment. The restructuring write off also reduces costs YOY into the future. The building blocks for a more solid albeit slightly boring NPAT recovery into the future are in place. The x factor is the opportunity for greater sales penetration offset with the currency risk.
Ann: Sirtex Records Underlying Full Year NPAT of $42.4 Million, page-30
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.008(4.92%) |
Mkt cap ! $67.91M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.5¢ | $399.7K | 2.5M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 141094 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |